Agilent Technologies announced EU certification for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for certain ovarian, fallopian tube, or primary peritoneal carcinomas. This expands the diagnostic's utility in identifying patients eligible for Merck's KEYTRUDA, representing a positive but incremental development for Agilent's diagnostics business.
Agilent Technologies received EU certification for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for specific ovarian, fallopian tube, and primary peritoneal carcinomas. This certification allows the diagnostic to identify patients whose tumors express PD-L1 and may be eligible for treatment with Merck's KEYTRUDA. This is a positive development for Agilent as it expands the market for its diagnostic product and for Merck by potentially increasing the patient pool for KEYTRUDA in the EU. While not a major financial catalyst, it represents continued growth and regulatory success for Agilent's diagnostics segment and reinforces KEYTRUDA's market position. For traders, this is a moderate positive for Agilent, indicating steady product expansion, and a minor positive for Merck, supporting its oncology franchise.